内源性大麻素系统在神经病理性疼痛中的作用和研究进展

The Role and Research Progress of the Endocannabinoid System in Neuropathic Pain

神经病理性疼痛(Neuropathic pain, NP)作为慢性疼痛的常见来源,其发病机制复杂且目前尚无有效治疗手段;又因其发病时产生持续的灼烧似疼痛而严重影响患者的正常生活,给个人和社会带来沉重负担。内源性大麻素系统(Endocannabinoid System, ECS)已被证实是内源性抗伤害系统的一部分, 包含多个有前景的NP治疗靶点:目前研究表明激活外周CB1受体通路、靶向激活CB2受体、抑制内源性大麻素降解酶和调节瞬态受体电位通道(TRP)等都是有效减轻NP症状的策略。本文主要从上述四个方面对ECS在疼痛管理中的作用和分子机制及相关NP治疗靶点的研究进展做一综述,以期为NP的治疗及ECS相关药物的开发提供理论支持。

Neuropathic pain (NP) is a common source of chronic pain. The pathogenesis of NP is complex and there is no effective treatment at present. Its onset can produce continuous burning pain and affect the normal life of patients seriously. NP imposes a heavy burden on individuals and society. The endocannabinoid system (ECS) has been proven to be a part of the endogenous anti-injury system and contains several promising NP therapeutic targets: current studies have demonstrated that activating peripheral CB1 receptor pathway, targeting activating CB2 receptors, inhibiting endocannabinoid degrading enzymes and regulating transient receptor potential channels (TRP) are potentially effective strategies for alleviating NP symptoms. In this paper, in order to provide theoretical support for the treatment of NP and the development of ECS-related drugs, the role and molecular mechanism of ECS in pain management and related NP therapeutic targets were reviewed from the above four aspects.